Search

Lanreotide

Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome … Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

Quinacrine

An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.

Telithromycin

Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis.

Roquinimex

Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

Cimlanod

Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)

Methacholine

[A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763] … [A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M₃ muscarinic receptors that stimulate ASM contraction

Mephenytoin

These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.

Ursodeoxycholic acid

[A256272] UDCA works by replacing the hydrophobic or more toxic bile acids from the bile acid pool.[A256272] … [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996.

V590

By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583].